MX2016002879A - Sistemas, dispositivos y metodos para la terapia anti-tl1a. - Google Patents
Sistemas, dispositivos y metodos para la terapia anti-tl1a.Info
- Publication number
- MX2016002879A MX2016002879A MX2016002879A MX2016002879A MX2016002879A MX 2016002879 A MX2016002879 A MX 2016002879A MX 2016002879 A MX2016002879 A MX 2016002879A MX 2016002879 A MX2016002879 A MX 2016002879A MX 2016002879 A MX2016002879 A MX 2016002879A
- Authority
- MX
- Mexico
- Prior art keywords
- systems
- methods
- patient
- tl1a
- disease
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title abstract 3
- 239000000090 biomarker Substances 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 2
- 208000011231 Crohn disease Diseases 0.000 abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 2
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 2
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 abstract 1
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7151—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF]; for lymphotoxin [LT]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361874487P | 2013-09-06 | 2013-09-06 | |
| PCT/US2014/054425 WO2015035261A1 (en) | 2013-09-06 | 2014-09-05 | Systems, devices and methods for anti-tl1a therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016002879A true MX2016002879A (es) | 2016-08-17 |
Family
ID=52628988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016002879A MX2016002879A (es) | 2013-09-06 | 2014-09-05 | Sistemas, dispositivos y metodos para la terapia anti-tl1a. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20160208329A1 (https=) |
| EP (1) | EP3041580A4 (https=) |
| JP (1) | JP2016536002A (https=) |
| KR (1) | KR20160052585A (https=) |
| CN (1) | CN105636648A (https=) |
| AU (1) | AU2014317991A1 (https=) |
| CA (1) | CA2922381A1 (https=) |
| IL (1) | IL244427A0 (https=) |
| MX (1) | MX2016002879A (https=) |
| WO (1) | WO2015035261A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| KR101982899B1 (ko) | 2011-09-30 | 2019-05-27 | 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 | ＴＬ1ａ에 대한 항체 및 그의 용도 |
| KR20230109779A (ko) | 2013-03-27 | 2023-07-20 | 세다르스-신나이 메디칼 센터 | Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한섬유증 및 염증의 완화 및 반전 |
| EP3022295A4 (en) | 2013-07-19 | 2017-03-01 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
| JP6692748B2 (ja) * | 2013-09-26 | 2020-05-13 | ナショナル ユニヴァーシティー オブ シンガポール | リゾホスファチジルコリンの足場を利用する組成物及び方法 |
| US20170246259A1 (en) * | 2014-09-10 | 2017-08-31 | Georgetown University | Compositions and Methods of Using Interleukin-4 Induced Gene 1 (IL-4I1) |
| JP2018522533A (ja) * | 2015-05-15 | 2018-08-16 | シーダーズ—シナイ メディカル センター | 炎症性腸疾患を処置するためのモデル、方法および組成物 |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| KR20240095481A (ko) * | 2016-03-17 | 2024-06-25 | 세다르스-신나이 메디칼 센터 | Rnaset2를 통한 염증성 장 질환의 진단 방법 |
| US10345302B2 (en) * | 2017-02-19 | 2019-07-09 | Sheng-He Huang | Circulating astrocytes and MFSD2A as biomarkers |
| CN106885902B (zh) * | 2017-03-03 | 2018-02-27 | 四川大学华西第二医院 | 以ncam‑1为检测指标的金标试剂盒及其制备方法和应用 |
| CN109954000B (zh) * | 2017-12-22 | 2021-02-23 | 中国农业大学 | 驴乳在制备食品或者药物中的用途、治疗溃疡性结肠炎的食品和药物 |
| WO2020112890A1 (en) | 2018-11-29 | 2020-06-04 | Cedars-Sinai Medical Center | Rnaset2 compositions and methods of treatment therewith |
| US12448651B2 (en) | 2018-12-12 | 2025-10-21 | Hadasit Medical Research Services And Development Ltd. | Markers of disease prognosis in multiple sclerosis |
| CA3180632A1 (en) * | 2020-06-03 | 2021-12-09 | Cedars-Sinai Medical Center | Methods and systems for measuring post-operative disease recurrence |
| BR112022025667A2 (pt) * | 2020-06-26 | 2023-03-07 | Pfizer | Métodos de tratamento da doença inflamatória intestinal com anticorpos tl1a |
| CN111979311A (zh) * | 2020-08-31 | 2020-11-24 | 西北大学 | 肌球蛋白1b作为动脉粥样硬化诊断和治疗靶标的应用 |
| CN112730850B (zh) * | 2021-01-22 | 2022-11-01 | 广州医科大学附属肿瘤医院 | 一种肾纤维化生物标志物及其应用 |
| CN115785277B (zh) * | 2022-09-09 | 2023-06-20 | 上海百英生物科技股份有限公司 | 一种抗IL4i1纳米抗体的制备及其应用 |
| CN121843714A (zh) | 2023-08-11 | 2026-04-10 | 派拉冈医疗公司 | Tl1a结合抗体及使用方法 |
| KR20250092108A (ko) * | 2023-12-12 | 2025-06-23 | 의료법인 성광의료재단 | 면역치료요법의 치료 반응 예측을 위한 바이오마커 및 이를 이용한 유전자 예측 모델 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6607879B1 (en) * | 1998-02-09 | 2003-08-19 | Incyte Corporation | Compositions for the detection of blood cell and immunological response gene expression |
| WO2005018571A2 (en) * | 2003-08-20 | 2005-03-03 | University Of Miami | Compositions and methods for treating inflammatory lung disease |
| AU2006284922B2 (en) * | 2005-08-30 | 2012-01-19 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists and immunotoxins |
| US20090186034A1 (en) * | 2006-12-19 | 2009-07-23 | Genetech, Inc. | Gene expression markers for inflammatory bowel disease |
| US9896511B2 (en) * | 2007-01-10 | 2018-02-20 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies |
| US20110217310A1 (en) * | 2007-01-10 | 2011-09-08 | Siegel Richard M | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology |
| US20100190162A1 (en) * | 2007-02-26 | 2010-07-29 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
| US8362218B2 (en) * | 2009-04-17 | 2013-01-29 | New York University School Of Medicine | Peptides targeting TNF family receptors and antagonizing TNF action, compositions, methods and uses thereof |
| WO2010144358A1 (en) * | 2009-06-08 | 2010-12-16 | Singulex, Inc. | Highly sensitive biomarker panels |
| WO2012161856A1 (en) * | 2011-05-20 | 2012-11-29 | Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof |
-
2014
- 2014-09-05 MX MX2016002879A patent/MX2016002879A/es unknown
- 2014-09-05 US US14/915,544 patent/US20160208329A1/en not_active Abandoned
- 2014-09-05 EP EP14842590.3A patent/EP3041580A4/en not_active Withdrawn
- 2014-09-05 AU AU2014317991A patent/AU2014317991A1/en not_active Abandoned
- 2014-09-05 CN CN201480057198.5A patent/CN105636648A/zh active Pending
- 2014-09-05 CA CA2922381A patent/CA2922381A1/en not_active Abandoned
- 2014-09-05 WO PCT/US2014/054425 patent/WO2015035261A1/en not_active Ceased
- 2014-09-05 JP JP2016540449A patent/JP2016536002A/ja not_active Withdrawn
- 2014-09-05 KR KR1020167007354A patent/KR20160052585A/ko not_active Withdrawn
-
2016
- 2016-03-03 IL IL244427A patent/IL244427A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL244427A0 (en) | 2016-04-21 |
| EP3041580A1 (en) | 2016-07-13 |
| US20160208329A1 (en) | 2016-07-21 |
| WO2015035261A1 (en) | 2015-03-12 |
| KR20160052585A (ko) | 2016-05-12 |
| CN105636648A (zh) | 2016-06-01 |
| EP3041580A4 (en) | 2017-05-03 |
| AU2014317991A1 (en) | 2016-03-10 |
| JP2016536002A (ja) | 2016-11-24 |
| CA2922381A1 (en) | 2015-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016002879A (es) | Sistemas, dispositivos y metodos para la terapia anti-tl1a. | |
| MX2015015784A (es) | Metodos para diagnosticar y tratar enfermedad inflamatoria de intestino. | |
| MX2016009060A (es) | Metodos y sistemas para determinar el riesgo de falla cardiaca. | |
| EP3043875A4 (en) | Method to determine body's physiological response to physical exercise for assessing readiness and to provide feedback, and system for implementing the method | |
| HUE058219T2 (hu) | FGFR-mutánsgénpanel alkalmazása olyan rákbetegek azonosításában, akik FGFR-inhibitorral történõ kezelésre reszponzívak lesznek | |
| IL235771A0 (en) | Respirometer system and data analysis methods | |
| MX2022010809A (es) | Antagonistas de integrina-beta7 para usarse en el tratamiento y diagnostico de trastornos inflamatorios gastrointestinales. | |
| MY194686A (en) | Detection of chromosome interactions | |
| NZ707035A (en) | Gene signatures of inflammatory disorders that relate to the liver | |
| EP3186397A4 (en) | Use of circulating cell biomarkers in the blood for detection and diagnosis of diseases and methods of isolating them | |
| BR112013004750A2 (pt) | derivados de quinolina e quinoxalina como inibidores da cinase | |
| HK1251655A1 (zh) | 通过线粒体分析预测对阿伏西地的应答 | |
| MX2017006959A (es) | Metodos para establecer un regimen de dosificacion de vedolizumab para tratar pacientes con enfermedad del intestino irritable. | |
| WO2014205266A3 (en) | Compositions and methods for detecting and treating glioblastoma | |
| UA118658C2 (uk) | СПОСІБ ДІАГНОСТИКИ ПРОГНОЗУ ВІДПОВІДІ НА ІНГІБІТОР TNFα | |
| NZ716643A (en) | Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event | |
| GB2515412A8 (en) | Assessing Physical Stability Of A Patient Using An Accelerometer | |
| MX2016003002A (es) | Metodos para determinar la respuesta a la terapia. | |
| EP3086846A4 (en) | Diagnosing and treating alzheimer's disease | |
| EP2908555A4 (en) | SYSTEM FOR ESTIMATING DEALERS VOLUME LEVELS, PROCESSOR FOR ESTIMATING DEVELOPERS VOLUME LEVELS, METHODS OF ESTIMATING PERSONNEL VOLUMES AND COMPUTER PROGRAM THEREFOR | |
| WO2016081885A3 (en) | Panel-based genetic diagnostic testing for inherited eye diseases | |
| WO2015069883A3 (en) | Oxidized fraction of extracellular dna as a biomarker of stress and methods for using the same | |
| MY185990A (en) | Marker for acid sphingomyelinase disorders and uses thereof | |
| MX2020006388A (es) | Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea. | |
| WO2014169011A3 (en) | Methods for treating immune diseases |